- Subject: Liquid Shark Cartilage Extract Shows Encouraging Results...
- From: AOL News <AOLNews@aol.com>
- Date: Mon, 30 Mar 1998 08:01:34 EST
- Organization: AOL (http://www.aol.com)
Liquid Shark Cartilage Extract Shows Encouraging Results to Cancer Experts
NEW ORLEANS, March 30 /PRNewswire/ -- A leading Canadian biotechnology
company, AEterna Laboratories, announced very encouraging results from a
clinical trial using liquid shark cartilage extract in lung cancer tumors in
humans. The results, presented today at the 89th Annual Meeting of the
American Association for Cancer Research, confirmed that AE-941 is the first
shark cartilage product to show a trend of efficacy without serious side
effects related to its administration.
The study was conducted on patients with refractory metastatic lung cancer
where they received one of four different doses of AE-941 for a three-month
period. The objective of the first part of the study was to establish the
safety profile of the product and determine the optimal dose for subsequent
studies.
Within the context of the rigorous U.S. and Canadian clinical trial standards,
AE-941 displayed no serious adverse events related to the administration of
the product. At no time was it necessary to suspend the administration of the
product to the patients because of adverse reactions. The study investigators
also found that the highest dose of AE-941 produced the greatest efficacy in
the patients.
"This trial conducted on late-stage cancer patients is an important milestone
in the clinical development of AE-941. More than 300 patients have received
the product in the last two years, some of them for more than 18 months," said
Dr. Riviere, MD, Vice President of Clinical Affairs at AEterna Laboratories.
"The second part of the Phase I/II study started recently in research centers
in Canada and the United States."
ANTIANGIOGENESIS LIQUID SHARK CARTILAGE EXTRACT
AE-941 is a liquid shark cartilage extract manufactured under patent, using
state-of-the-art cell fractionation and molecular isolation techniques. It is
expected to inhibit the growth and spread of cancer tumors by reducing the
blood supply to tumor cells in the body. AE-941 has reduced the number of
metastases and the growth of the primary tumor in animal studies. Animal
models showed a significant 70 per cent reduction in the number of lung
metastases and a 60 per cent reduction in the growth of breast primary tumors.
Some new drugs under clinical investigation have serious side effects that
limit their further development. Side effects are the primary reason that
patients must stop cancer treatments, namely chemotherapy-based treatments.
According to the new AE-941 clinical trial results, AE-941 is the first shark
cartilage product to show a trend of efficacy without serious side effects
related to its oral administration.
"Results obtained to date are very encouraging. An angiogenesis inhibitor has
to be administered orally and have minimal or no toxicity in order for the
patients to benefit from a long-term administration of a such product," said
Dr. Jean Latreille, MD, an oncologist at the Centre Hospitalier de
l'Universite de Montreal, Hotel-Dieu Campus and Principal Investigator of this
clinical trial. "If the results obtained to date are confirmed while keeping
the same type of safety profile, AE-941 could well become a first-line
therapeutic weapon to treat cancers."
"We are very pleased with the first results obtained with the collaboration of
several university hospitals. These results were well received by the
scientific community and enable the company to continue the development of
AE-941 as a treatment for lung cancer. The next steps of AE- 941's development
will have to confirm the product's efficacy on a larger number of patients,"
commented Dr. Dupont, Ph.D., President and CEO of AEterna Laboratories.
U.S. CLINICAL TRIAL SITES
U.S. and Canadian cancer researchers are encouraged with recent trial results.
Several world-renowned cancer research centers have agreed to participate in
clinical trials, including the University of Texas MD Anderson Cancer Center
and the North Shore - LIJ Health System in New York. AEterna begun testing
AE-941 in the United States after receiving approval of their investigational
new drug (IND) application in January, 1997.
The Phase I/II lung cancer results have already been released in Canada under
the Timely Disclosure Policy of the Market Surveillance and Disclosure of the
Toronto and Montreal Stock Exchanges.
AEterna Laboratories performs research and development activities on drugs
that can control diseases complicated by angiogenesis. AEterna is a leading
biotechnology company in Canada and is a world leader in the development of
anti-angiogenic therapies. All studies on AE-941 have not been completed.
Consequently, AE-941 has not been approved yet by competent authorities for
its commercialization.
SOURCE AEterna Laboratories
CO: AEterna Laboratories
ST: Louisiana, Quebec
IN: MTC
SU:
03/30/98 07:58 EST http://www.prnewswire.com
To edit your profile, go to keyword <A HREF="aol://1722:NewsProfiles">
NewsProfiles</A>.
For all of today's news, go to keyword <A HREF="aol://1722:News">News</A>.
